Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.54 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.52 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.52 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butane SCHEMBL27323486 | 0.93 | GNAI3 (0.59) | SOS1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL4634177 | 0.88 | KCNH2 (0.57) | SOS1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL20648825 | 0.88 | GNAI3 (0.58) | SOS1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL19560897 | 0.86 | GNAI3 (0.61) | SOS1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL19604920 | 0.85 | GNAI3 (0.64) | SOS1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL4668397 | 0.84 | — | — | |
| SCHEMBL20626535 | 0.84 | SOS1 (0.51) | SOS1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL27909545 | 0.84 | SOS1 (0.51) | SOS1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL21218127 | 0.82 | GNAI3 (0.51) | SOS1GNAI3GNAO1GNAI1KCNH2 | |
| SCHEMBL5646115 | 0.80 | GNAI3 (0.47) | SOS1GNAI3GNAO1GNAI1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210094912-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERISTY OF NEW JERSEY (US) | 2021-04-01 | — | — | US | disclosed |
| WO-2018140809-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-08-02 | — | — | WO | disclosed |
| US-9815834-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815834-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-20160229849-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-08-11 | — | — | US | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8324265-B2 | Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| US-8324265-B2 | Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| CN-1871215-B | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO | 2011-06-08 | — | — | CN | disclosed |
| US-20090170832-A1 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090170832-A1 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| CN-1871215-A | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2006-11-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | SOS1 1447/4885GNAI3 1103/4885GNAO1 1410/4885 |
| US-20210094912-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, ABCG2 | SOS1 2695/4885GNAI3 412/4885GNAO1 1747/4885 |
| US-20090170832-A1 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | HSD17B1, HSD11B1, HSD3B1 | SOS1 1447/4885GNAI3 1745/4885GNAO1 448/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | SOS1 1447/4885GNAI3 1103/4885GNAO1 1410/4885 |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | MPL, MTX2, SLC10A1 | SOS1 4020/4885GNAI3 3008/4885GNAO1 3626/4885 |
| US-20160229849-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | SOS1 1750/4885GNAI3 743/4885GNAO1 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.